EAM
AVTX icon

Exome Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Exome Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.38M Buy
+159,341
New +$2.49M 1.23% 35
2025
Q4 		– Sell
-100,036
Closed -$1.27M – 65
2025
Q3 		$1.27M Buy
+100,036
New +$860K 0.77% 47

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Exome Asset Management's AVTX Position: Q1 2026 in Review

Exome Asset Management opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 159,341 shares worth $2.38M. The stake represents 1.23% of the portfolio and ranks #35 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in AVTX as recently as Q3 2025.

Exome Asset Management first reported a position in AVTX in Q3 2025 and has held it in 2 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Exome Asset Management held 159,341 shares of Avalo Therapeutics worth $2.38M as of Q1 2026.
  • Avalo Therapeutics was a new Exome Asset Management position in Q1 2026.
  • Avalo Therapeutics made up 1.23% of Exome Asset Management's portfolio in Q1 2026, its #35 holding.
  • Exome Asset Management first reported a position in Avalo Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.